Forsta AP Fonden Purchases New Position in Shire (SHPG)

Forsta AP Fonden purchased a new stake in Shire (NASDAQ:SHPG) during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 100,000 shares of the biopharmaceutical company’s stock, valued at approximately $14,939,000.

Other institutional investors also recently added to or reduced their stakes in the company. SeaCrest Wealth Management LLC purchased a new position in Shire in the 4th quarter valued at $107,000. Avestar Capital LLC purchased a new position in Shire in the 4th quarter valued at $116,000. Amica Retiree Medical Trust purchased a new position in shares of Shire during the 4th quarter worth $120,000. Benjamin F. Edwards & Company Inc. raised its holdings in shares of Shire by 277.4% during the 4th quarter. Benjamin F. Edwards & Company Inc. now owns 1,253 shares of the biopharmaceutical company’s stock worth $194,000 after acquiring an additional 921 shares during the period. Finally, Sawtooth Solutions LLC purchased a new position in shares of Shire during the 4th quarter worth $200,000. 18.08% of the stock is currently owned by hedge funds and other institutional investors.

Several research firms have recently commented on SHPG. Royal Bank of Canada set a $192.00 price target on Shire and gave the stock a “buy” rating in a report on Monday, February 5th. Cantor Fitzgerald set a $222.00 price target on Shire and gave the stock a “buy” rating in a report on Wednesday, March 28th. B. Riley reduced their price target on Shire from $201.00 to $181.00 and set a “buy” rating on the stock in a report on Friday, February 16th. ValuEngine lowered Shire from a “hold” rating to a “sell” rating in a report on Wednesday, May 2nd. Finally, Zacks Investment Research upgraded Shire from a “sell” rating to a “hold” rating in a report on Friday, March 23rd. One research analyst has rated the stock with a sell rating, eight have issued a hold rating and twelve have given a buy rating to the stock. The stock has an average rating of “Buy” and a consensus price target of $201.64.

NASDAQ SHPG opened at $171.65 on Friday. The stock has a market capitalization of $52.62 billion, a price-to-earnings ratio of 11.33, a PEG ratio of 1.37 and a beta of 1.30. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.14 and a quick ratio of 0.66. Shire has a 1-year low of $169.82 and a 1-year high of $171.12.

Shire (NASDAQ:SHPG) last released its earnings results on Thursday, April 26th. The biopharmaceutical company reported $3.86 earnings per share for the quarter, beating the consensus estimate of $3.58 by $0.28. The company had revenue of $3.77 billion during the quarter. Shire had a return on equity of 13.60% and a net margin of 28.96%. The business’s revenue was up 5.4% compared to the same quarter last year. During the same period in the prior year, the firm earned $3.63 earnings per share. sell-side analysts forecast that Shire will post 15.26 earnings per share for the current fiscal year.

About Shire

Shire plc, a biotechnology company, researches, develops, licenses, manufactures, markets, distributes, and sells medicines for rare diseases and other specialized conditions worldwide. The company offers products in therapeutic areas, including hematology, genetic diseases, neuroscience, immunology, internal medicine, ophthalmology, and oncology.

Want to see what other hedge funds are holding SHPG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Shire (NASDAQ:SHPG).

Institutional Ownership by Quarter for Shire (NASDAQ:SHPG)

Receive News & Ratings for Shire Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply